Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea

Background: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-infammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap. Methods: Plasma levels of sRAGE were measured in 31...

Descripción completa

Detalles Bibliográficos
Autores: Marin-Oto, Marta, Sanz Rubio, David, Santamaría Martos, Fernando, Benítez, Iván, Simon, Ana L., Forner, Marta, Cubero, Pablo, Gil, Ana, Sánchez de la Torre, Manuel, Barbé Illa, Ferran, Marin, José M.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/84375
Acceso en línea:https://doi.org/10.1186/s12931-022-02092-9
http://hdl.handle.net/10459.1/84375
Access Level:acceso abierto
Palabra clave:SRAGE
Smokers
Chronic obstructive pulmonary disease
Obstructive sleep apnoea
id ES_e540b39e4140ee7a3283b3f7153500a1
oai_identifier_str oai:repositori.udl.cat:10459.1/84375
network_acronym_str ES
network_name_str España
repository_id_str
spelling Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoeaMarin-Oto, MartaSanz Rubio, DavidSantamaría Martos, FernandoBenítez, IvánSimon, Ana L.Forner, MartaCubero, PabloGil, AnaSánchez de la Torre, ManuelBarbé Illa, FerranMarin, José M.SRAGESmokersChronic obstructive pulmonary diseaseObstructive sleep apnoeaBackground: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-infammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap. Methods: Plasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers [HNS], 84 healthy smokers [HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap). Results: After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (− 12.5%, p=0.005), COPD (− 14.8%, p<0.001) and OSA-COPD overlap (− 12.3%, p=0.02) compared with HNS. There were no diferences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change signifcantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased signifcantly. Conclusions: The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD.The EPIOSA study (NCT02131610) was supported by Grants Number PI12/02175, PI15/01940 and PI18/01524 from the Instituto Salud Carlos III, Spanish Ministry of Health, Madrid, Spain and the European Regional Development Fund (FEDER) and by a Grant Number 01/2010 from the SADAR-Pneumo Aragón, Zaragoza, Spain.BMC2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1186/s12931-022-02092-9http://hdl.handle.net/10459.1/84375reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)Inglésinfo:eu-repo/grantAgreement/MINECO//PI12%2F02175info:eu-repo/grantAgreement/MINECO//PI15%2F01940info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F01524Reproducció del document publicat a https://doi.org/10.1186/s12931-022-02092-9Respiratory Research, 2022, vol. 23, art. 163cc-by (c) Marta Marin‑Oto et. al., 2022info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:repositori.udl.cat:10459.1/843752026-06-24T12:42:17Z
dc.title.none.fl_str_mv Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
title Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
spellingShingle Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
Marin-Oto, Marta
SRAGE
Smokers
Chronic obstructive pulmonary disease
Obstructive sleep apnoea
title_short Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
title_full Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
title_fullStr Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
title_full_unstemmed Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
title_sort Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
dc.creator.none.fl_str_mv Marin-Oto, Marta
Sanz Rubio, David
Santamaría Martos, Fernando
Benítez, Iván
Simon, Ana L.
Forner, Marta
Cubero, Pablo
Gil, Ana
Sánchez de la Torre, Manuel
Barbé Illa, Ferran
Marin, José M.
author Marin-Oto, Marta
author_facet Marin-Oto, Marta
Sanz Rubio, David
Santamaría Martos, Fernando
Benítez, Iván
Simon, Ana L.
Forner, Marta
Cubero, Pablo
Gil, Ana
Sánchez de la Torre, Manuel
Barbé Illa, Ferran
Marin, José M.
author_role author
author2 Sanz Rubio, David
Santamaría Martos, Fernando
Benítez, Iván
Simon, Ana L.
Forner, Marta
Cubero, Pablo
Gil, Ana
Sánchez de la Torre, Manuel
Barbé Illa, Ferran
Marin, José M.
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv SRAGE
Smokers
Chronic obstructive pulmonary disease
Obstructive sleep apnoea
topic SRAGE
Smokers
Chronic obstructive pulmonary disease
Obstructive sleep apnoea
description Background: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-infammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap. Methods: Plasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers [HNS], 84 healthy smokers [HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap). Results: After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (− 12.5%, p=0.005), COPD (− 14.8%, p<0.001) and OSA-COPD overlap (− 12.3%, p=0.02) compared with HNS. There were no diferences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change signifcantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased signifcantly. Conclusions: The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1186/s12931-022-02092-9
http://hdl.handle.net/10459.1/84375
url https://doi.org/10.1186/s12931-022-02092-9
http://hdl.handle.net/10459.1/84375
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/MINECO//PI12%2F02175
info:eu-repo/grantAgreement/MINECO//PI15%2F01940
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F01524
Reproducció del document publicat a https://doi.org/10.1186/s12931-022-02092-9
Respiratory Research, 2022, vol. 23, art. 163
dc.rights.none.fl_str_mv cc-by (c) Marta Marin‑Oto et. al., 2022
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Marta Marin‑Oto et. al., 2022
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422662365741056
score 15,81155

Similares en LA Referencia